参考文献 References
[1] Lee JH, Ju HJ, Seo JM, et al. Comorbidities in Patients with Vitiligo[J]. J Invest Dermatol. 2023;143(5):777-789.e6.
[2] Lim HK, Bae MI, Jeong KH, et al. Positivity rates of antithyroid antibody, antinuclear antibody and thyroid peroxidase antibody in different types of vitiligo[J]. Clin Exp Dermatol. 2016;41(3):242-247.
[3] Yuan J, Sun C, Jiang S, et al. The Prevalence of Thyroid Disorders in Patients With Vitiligo[J]. Front Endocrinol (Lausanne). 2018;9:803.
[4] Fan KC, Yang TH, and Huang YC. Vitiligo and thyroid disease[J]. Eur J Dermatol. 2018;28(6):750-763.
[5] Tang Q, Sousa J, Echeverria D, et al. RNAi-based modulation of IFN-γ signaling in skin[J]. Mol Ther. 2022;30(8):2709-2721.
[6] Maouia A, Sormani L, Youssef M, et al. Differential expression of CXCL9, CXCL10, and IFN-γ in vitiligo and alopecia areata patients[J]. Pigment Cell Melanoma Res. 2017;30(2):259-261.
[7] Spritz RA, and Santorico SA. The Genetic Basis of Vitiligo[J]. J Invest Dermatol. 2021;141(2):265-273.
[8] Barbulescu CC, Goldstein NB, Roop DR, et al. Harnessing the Power of Regenerative Therapy for Vitiligo and Alopecia Areata[J]. J Invest Dermatol. 2020;140(1):29-37.
[9] Moya EC, Bruinsma RL, Kelly KA, et al. How suitable are JAK inhibitors in treating the inflammatory component in patients with alopecia areata and vitiligo?[J]. Expert Rev Clin Immunol. 2022;18(3):189-191.
[10] Hu S, Che Y, Cai J, et al. Diabetes, glycemic profile and risk of vitiligo[J]. Skin Res Technol. 2024;30(7):e13787.
[11] Márquez A, and Martín J. Genetic overlap between type 1 diabetes and other autoimmune diseases[J]. Semin Immunopathol. 2022;44(1):81-97.
[12] Hadi A, Wang JF, Uppal P, et al. Comorbid diseases of vitiligo[J]. J Am Acad Dermatol. 2020;82(3):628-633.
[13] Zhao M, Zhang Y, and Sun G. Identifying the genetic association between common rheumatic diseases and vitiligo[J]. Skin Res Technol. 2024;30(7):e13846.
[14] Fichna M, Małecki PP, Młodzikowska M, et al. Increased risk of endocrine autoimmunity in first-degree relatives of patients with autoimmune Addison’s disease[J]. Eur J Endocrinol. 2020;183(1):73-81.
[15] Fichna M, Żurawek M, Słomiński B, et al. Polymorphism in BACH2 gene is a marker of polyglandular autoimmunity[J]. Endocrine. 2021;74(1):72-79.
[16] Zwick D, Vo MT, Shim YJ, et al. BACH2[J]. Cells. 2024; 13(11):891.
[17] Chuang KW, and Chang HC. Association between vitiligo and metabolic syndrome[J]. J Dtsch Dermatol Ges. 2022;20(2): 218-221.
[18] Kridin K, Lyakhovitsky K, Barhoum M, et al. Vitiligo and the metabolic syndrome[J]. Arch Dermatol Res. 2024;316(7):408.
[19] Namazi N, Amani M, Haghighatkhah HR, et al. Increased risk of subclinical atherosclerosis and metabolic syndrome in patients with vitiligo[J]. Dermatol Ther. 2021;34(2):e14803.
[20] Genedy R, Assal S, Gomaa A, et al. Ocular and auditory abnormalities in patients with vitiligo[J]. Clin Exp Dermatol. 2021;46(6):1058-1066.
[21] Ezzedine K, Soliman AM, Li C, et al. Comorbidity Burden Among Patients with Vitiligo in the United States[J]. Dermatol Ther (Heidelb). 2023;13(10):2265-2277.
[22] Ma SH, Ang MD, Chang YT, et al. Association between vitiligo and hearing loss[J]. J Am Acad Dermatol. 2021; 85(6):1465-1472.
[23] Lien KH, Ger TY, and Chi CC. Association of vitiligo with high-frequency sensorineural hearing loss[J]. J Eur Acad Dermatol Venereol. 2022;36(3):373-379.
[24] Baizabal-Carvallo JF, and Alonso-Juarez M. Cerebellar disease associated with anti-glutamic acid decarboxylase antibodies[J]. J Neural Transm (Vienna). 2017;124(10):1171-1182.
[25] Bai L, Ren H, Liang M, et al. Neurological disorders associated with glutamic acid decarboxylase 65 antibodies[J]. Front Neurol. 2022;13:990553.
[26] Wang Y, Yao T, Lin Y, et al. Exploring genetic associations between vitiligo and mental disorders using Mendelian randomization[J]. Exp Dermatol. 2024;33(1):e14979.
[27] Seneschal J. Clinical Features of Vitiligo and Social Impact on Quality of Life[J]. Dermatol Pract Concept. 2023;13(4S2): e2023312S.
[28] Simons RE, Zevy DL, and Jafferany M. Psychodermatology of vitiligo[J]. Dermatol Ther. 2020;33(3):e13418.
[29] Ramot Y, Rosenberg V, Zhou L, et al. Epidemiology and Treatment Patterns of Patients with Vitiligo[J]. Adv Ther. 2024;41(7):2890-2906.
[30] Kussainova A, Kassym L, Akhmetova A, et al. Vitiligo and anxiety[J]. PLoS One. 2020;15(11):e0241445.